Should I buy or sell Cellectis stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLLS shares. View CLLS analyst ratings or view top-rated stocks .

What is Cellectis' stock price target for 2024?

2 analysts have issued 1-year target prices for Cellectis' stock. Their CLLS share price targets range from $6.00 to $11.00. On average, they anticipate the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 244.1% from the stock's current price. View analysts price targets for CLLS or view top-rated stocks among Wall Street analysts .

How have CLLS shares performed in 2024?

Cellectis' stock was trading at $3.08 at the start of the year. Since then, CLLS shares have decreased by 19.8% and is now trading at $2.47. View the best growth stocks for 2024 here .

When is Cellectis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CLLS earnings forecast .

How were Cellectis' earnings last quarter?

Cellectis S.A. (NASDAQ:CLLS) issued its earnings results on Wednesday, December, 8th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by $0.02. Cellectis had a negative net margin of 346.65% and a negative trailing twelve-month return on equity of 73.03%.

What is André Choulika's approval rating as Cellectis' CEO?

13 employees have rated Cellectis Chief Executive Officer André Choulika on Glassdoor.com . André Choulika has an approval rating of 100% among the company's employees. This puts André Choulika in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 39.0% of employees surveyed would recommend working at Cellectis to a friend.

What other stocks do shareholders of Cellectis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Gilead Sciences (gild) , Calyxt (CLXT) , NVIDIA (NVDA) , AbbVie (ABBV) , Micron Technology (MU) , Advanced Micro Devices (AMD) , CRISPR Therapeutics (CRSP) , Editas Medicine (EDIT) , Intel (INTC) and Sorrento Therapeutics (SRNE) .

When did Cellectis IPO?

Cellectis (CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

How do I buy shares of Cellectis?

Shares of CLLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CLLS

Cellectis (CLLS) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free CLLS Stock Alerts

$2.47

+0.01 (+0.41%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.30
▼
$2.63
50-Day Range: $2.41
▼
$3.06
52-Week Range: $0.96
▼
$3.77

Volume: 14,972 shs
Average Volume: 41,272 shs
Market Capitalization: $137.28 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.50

Get Cellectis alerts:

Cellectis MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 244.1% Upside
$8.50 Price Target
Short Interest: Bearish
1.22% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.53) to ($1.06) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.19 out of 5 stars

Medical Sector

474th out of 918 stocks

Biological Products, Except Diagnostic Industry

70th out of 147 stocks

3.5

Analyst's Opinion

Consensus Rating
Cellectis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Cellectis has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
1.22% of the outstanding shares of Cellectis have been sold short.
Short Interest Ratio / Days to Cover
Cellectis has a short interest ratio ("days to cover") of 16.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Cellectis has recently decreased by 0.41%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Cellectis does not currently pay a dividend.
Dividend Growth
Cellectis does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CLLS.

1.1

News and Social Media Coverage

News Sentiment
Cellectis has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Cellectis this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added Cellectis to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cellectis insiders have not sold or bought any company stock.
Percentage Held by Insiders
16.41% of the stock of Cellectis is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
63.90% of the stock of Cellectis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Cellectis are expected to grow in the coming year, from ($1.53) to ($1.06) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cellectis is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cellectis is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cellectis has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Cellectis Stock (NASDAQ:CLLS)

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

CLLS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CLLS Stock News Headlines

April 13, 2024 | americanbankingnews.com

Cellectis (NASDAQ:CLLS) Rating Lowered to Sell at StockNews.com

April 11, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading

April 19, 2024 | InvestorPlace (Ad)

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 10, 2024 | finance.yahoo.com

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs

April 10, 2024 | globenewswire.com

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs

April 10, 2024 | americanbankingnews.com

Cellectis (NASDAQ:CLLS) Shares Cross Above 50 Day Moving Average of $2.71

April 8, 2024 | globenewswire.com

Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting

March 27, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading

April 19, 2024 | InvestorPlace (Ad)

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 11, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading

February 24, 2024 | finance.yahoo.com

Cellectis S.A. (CLLS)

February 20, 2024 | wsj.com

Cellectis S.A. ADR

February 3, 2024 | finance.yahoo.com

Monthly information on share capital and company voting rights

January 26, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, End Week Up 2.6%

January 16, 2024 | msn.com

Cellectis draws down second tranche under EIB credit facility

January 16, 2024 | finance.yahoo.com

Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

December 22, 2023 | finance.yahoo.com

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

December 16, 2023 | msn.com

Cellectis - ADR (CLLS) Price Target Increased by 20.85% to 11.75

November 17, 2023 | finance.yahoo.com

Cellectis’ Shareholders Meeting to be Held on December 22, 2023

November 15, 2023 | finance.yahoo.com

Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

November 12, 2023 | morningstar.com

Cellectis SA ADR CLLS

November 8, 2023 | finance.yahoo.com

Cellectis S.A. (NASDAQ:CLLS) Q3 2023 Earnings Call Transcript

November 8, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Cellectis SA (CLLS), Agenus (AGEN) and OrthoPediatrics (KIDS)

November 6, 2023 | seekingalpha.com

Cellectis Non-GAAP EPS of -$0.58, revenue of $1.88M

November 3, 2023 | benzinga.com

Earnings Preview: Cellectis

November 2, 2023 | finance.yahoo.com

Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting

November 1, 2023 | msn.com

Cellectis - ADR (CLLS) Price Target Increased by 11.03% to 11.29

See More Headlines

Receive CLLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 12/08/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:CLLS
CUSIP: N/A
CIK: 1627281
Web: www.cellectis.com
Phone: (318) 169-1600
Fax: 33-1-81-69-16-06
Employees: 231
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.50
High Stock Price Target: $11.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +269.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.67)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-106,140,000.00
Net Margins: -346.65%
Pretax Margin: -320.53%
Return on Equity: -73.03%
Return on Assets: -32.22%

Debt

Debt-to-Equity Ratio: 0.57
Current Ratio: 2.20
Quick Ratio: 2.20

Sales & Book Value

Annual Sales: $25.73 million
Price / Sales: 4.97
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.76 per share
Price / Book: 0.83

Miscellaneous

Outstanding Shares: 55,580,000
Free Float: 46,463,000
Market Cap: $127.83 million
Optionable: Optionable
Beta: 3.12

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Andre Choulika Ph.D. (Age 59)
Co-Founder, CEO & Director
Comp: $744.02k
Dr. David j. d. Sourdive Ph.D. (Age 57)
Deputy CEO, Executive VP of CMC & Manufacturing and Director
Comp: $528.92k
Dr. Bing C. Wang M.B.A. (Age 47)
Ph.D., Chief Financial Officer
Valerie Cros
Principal Financial Officer & Principal Accounting Officer
Mr. Jean Charles Epinat
Chief Technological Officer
Dr. Philippe Duchateau Ph.D. (Age 61)
Chief Scientific Officer
Mr. Stephan Reynier M.Sc. (Age 55)
Chief Regulatory & Pharmaceutical Compliance Officer
Ms. Marie-Bleuenn Terrier (Age 42)
General Counsel & Secretary of the Board of Directors
Pascalyne Wilson
Director of Communications
Ms. Kyung Nam-Wortman (Age 54)
Executive VP & Chief Human Resources Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CLLS Stock Analysis - Frequently Asked Questions

Should I buy or sell Cellectis stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLLS shares.
View CLLS analyst ratings or view top-rated stocks.
What is Cellectis' stock price target for 2024?: 2 analysts have issued 1-year target prices for Cellectis' stock. Their CLLS share price targets range from $6.00 to $11.00. On average, they anticipate the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 244.1% from the stock's current price.
View analysts price targets for CLLS or view top-rated stocks among Wall Street analysts.
How have CLLS shares performed in 2024?: Cellectis' stock was trading at $3.08 at the start of the year. Since then, CLLS shares have decreased by 19.8% and is now trading at $2.47.
View the best growth stocks for 2024 here.
When is Cellectis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CLLS earnings forecast.
How were Cellectis' earnings last quarter?: Cellectis S.A. (NASDAQ:CLLS) issued its earnings results on Wednesday, December, 8th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by $0.02. Cellectis had a negative net margin of 346.65% and a negative trailing twelve-month return on equity of 73.03%.

What is André Choulika's approval rating as Cellectis' CEO?: 13 employees have rated Cellectis Chief Executive Officer André Choulika on Glassdoor.com. André Choulika has an approval rating of 100% among the company's employees. This puts André Choulika in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 39.0% of employees surveyed would recommend working at Cellectis to a friend.
What other stocks do shareholders of Cellectis own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Gilead Sciences (gild), Calyxt (CLXT), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Intel (INTC) and Sorrento Therapeutics (SRNE).
When did Cellectis IPO?: Cellectis (CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.
How do I buy shares of Cellectis?: Shares of CLLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLLS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cellectis (CLLS) Stock Price, News & Analysis

Cellectis MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Cellectis Stock (NASDAQ:CLLS)

CLLS Stock Price History

CLLS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

CLLS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™